✦ LIBER ✦

PDG6: COST-EFFECTIVENESS OF PIOGLITAZONE (ACTOS®, TAKEDA) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN SWEDEN

✍ Scribed by F Henriksson; A Brandt; L Thomander; A Kielhorn; R Jansen; N Maniadakis

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDG14: AN ASSESSMENT OF THE COSTEFFECTIV

✍ R Jansen; JO Clausen; N Maniadakis; A Kielhorn; A Brandt 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PDG11: HEALTH AND ECONOMIC OUTCOMES OF A

✍ A Brandt; K Frislid; R Jansen; N Maniadakis; A Kielhorn 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

PDG3: AN ECONOMIC EVALUATION OF COMBINAT

✍ N Maniadakis; J Sacristan; J Reviriego; W Hart; R Jansen; A Kielhorn; A Brandt 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

PDG1: THE OUTCOMES OF LONG-TERM TREATMEN

✍ N Maniadakis; A Kielhorn; K Heikkinen; A Brandt; R Jansen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

PROactive 06: cost-effectiveness of piog

✍ W. J. Valentine; J. M. Bottomley; A. J. Palmer; M. Brändle; V. Foos; R. Williams 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB

Cost-effectiveness of saxagliptin (Ongly

✍ Granström, Ola; Bergenheim, Klas; McEwan, Phil; Sennfält, Karin; Henriksson, Mar 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 602 KB